Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 1, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, February 28, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ed Arce Initiated (TVTX) at Strong Buy and Held Target at $45 on, Feb 28th, 2022
Ed Arce of HC Wainwright & Co., Initiated "Travere Therapeutics, Inc." (TVTX) at Strong Buy and Held Target at $45 on, Feb 28th, 2022.
Ed has made no other calls on TVTX in the last 4 months.
There are 2 other peers that have a rating on TVTX. Out of the 2 peers that are also analyzing TVTX, 0 agree with Ed's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Ed
- Carter Gould of "Barclays" Maintained at Buy with Increased Target to $40 on, Thursday, December 16th, 2021
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $42 on, Thursday, December 16th, 2021
